Rexahn Pharmaceuticals (NYSEMKT:RNN) has tumbled 8.05% during the past week and has dropped 8.05% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 6.95%. Rexahn Pharmaceuticals (NYSEMKT:RNN) has underperformed the index by 8.89% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Rexahn Pharmaceuticals (NYSEMKT:RNN): The stock opened at $0.26 on Friday but the bulls could not build on the opening and the stock topped out at $0.26 for the day. The stock traded down to $0.25 during the day, due to lack of any buying support eventually closed down at $0.25 with a loss of -2.34% for the day. The stock had closed at $0.26 on the previous day. The total traded volume was 1,966,567 shares.
The company shares have dropped -62.69% from its 1 Year high price. On Jun 26, 2015, the shares registered one year high at $0.69 and the one year low was seen on Jun 17, 2016. The 50-Day Moving Average price is $0.28 and the 200 Day Moving Average price is recorded at $0.34.
On the companys insider trading activities, The Securities and Exchange Commission has divulged that Jeong Tae Heum, officer (Chief Financial Officer) of Rexahn Pharmaceuticals, Inc., had unloaded 317,272 shares at an average price of $0.91 in a transaction dated on January 8, 2015. The total value of the transaction was worth $288,718.
Currently the company Insiders own 5.9% of Rexahn Pharmaceuticals shares according to the proxy statements. Institutional Investors own 10.66% of Rexahn Pharmaceuticals shares.
Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of treatments for cancer and other medical needs. The Company has three clinical stage drug candidates in active development: Archexin, a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance; RX-3117, a small molecule nucleoside compound with an anti-metabolite mechanism of action and has therapeutic potential in a range of cancers, including colon, lung and pancreatic cancer, and Supinoxin (RX-5902), a small molecule that inhibits the phosphorylation of p68, which is expressed in cancer cells, but not in normal cells, results in up-regulation of cancer-related genes and a subsequent proliferation or tumor growth of cancer cells. The Company also has two drug candidates in pre-clinical development: Archexin-Nano and RX-21101.